Clinical Trial Update: Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating bendamustine hydrochloride, rituximab, etoposide, and carboplatin in relapsed/refractory diffuse large B-cell lymphoma or Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Rituximab (rituximab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-25